MicroRNAs in lung cancer
Metrics: PDF 1456 views | HTML 2966 views | ?
Diana Castro1, Márcia Moreira1, Alexandra Monteiro Gouveia1,2,3, Daniel Humberto Pozza1,3 and Ramon Andrade De Mello4,5,6
1Department of Experimental Biology, Faculty of Medicine, University of Porto, Porto, Portugal
2Institute for Cellular and Molecular Biology (IBMC), Institute for Health Innovation, University of Porto, Porto, Portugal
3Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal
4Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal
5Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal
6Cearense School of Oncology, Ceará Cancer Institute, Fortaleza, Brazil
Ramon Andrade De Mello, email: firstname.lastname@example.org
Keywords: microRNAs, lung cancer, inflammation, epithelial mesenchymal transition, interleukin 1
Received: April 12, 2017 Accepted: August 26, 2017 Published: September 16, 2017
Lung cancer (LC) is a serious public health problem responsible for the majority of cancer deaths and comorbidities in developed countries. Tobacco smoking is considered the main risk factor for LC; however, only a few smokers will be affected by this cancer. Current screening methods are focused on identifying the early stages of this malignancy. Thus, new data concerning the roles of microRNA alterations in inflammation, epithelial-mesenchymal transition and lung disease have increased hope about LC pathogenesis, diagnosis, treatment and prognosis. MicroRNA mechanisms include angiogenesis promotion, cell cycle regulation by modulating cellular proliferation and apoptosis, and migration and invasion inhibition. In this context, this manuscript reviews the current information about many important microRNAs as they relate to the initiation and progression of LC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.